BioSpace News Archive

Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing (cGMP) facility.

According to the current analysis of Reports and Data, the global Hypertrophic Cardiomyopathy Therapeutics Market valued at USD 1.20 Billion in 2019 and is expected to reach USD 1.42 billion by the year 2027, at a CAGR of 2.1%.

Urologists at Hackensack University Medical Center have become the first in northern New Jersey to offer an innovative treatment for benign prostatic hyperplasia that uses a high-intensity waterjet to destroy excess prostate tissue that causes uncomfortable urinary symptoms for many older men.

Wenzel Spine, Inc., today announced the launch of the S-LIF Procedure for Stand-alone Lumbar Interbody Fusion using the VariLift®-LX device, the only stand-alone expandable posterior lumbar interbody fusion device that is FDA-cleared for 1 or 2 level fusion.

Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, Inc., announced today the findings of a study that showed paired RNA and DNA genetic testing, conducted at the same time, detected elusive pathogenic variants in 1 of every 950 patients that were missed by DNA testing alone.

Daré Bioscience, Inc. today announced that, based on the results of an interim analysis to evaluate the relative magnitude of the treatment effect, they expect to complete enrollment in the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in 4Q-2022, allowing for a topline data announcement target of 2Q-2023.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Citi 17th Annual BioPharma Conference at the Four Seasons Hotel in Boston on September 8, 2022.

BrainsWay Ltd. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Deep TMS™ H7 Coil for its use in treating adults suffering from major depressive disorder and depression.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor conferences.

iCAD, Inc. today announced that a growing number of hospitals and imaging centers in the U.S. and Europe are increasingly choosing to adopt iCAD’s Breast AI Suite, which includes ProFound AI ® , ProFound AI ® Risk, and PowerLook ® Density Assessment, via a subscription model.